Harrow Health, Inc. (NASDAQ:HROW) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to Harrow's First Quarter 2026 Earnings Conference Call. My name is Michelle, and I will be your operator for today's call.
Harrow Inc. (HROW)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 2,832,230 | $99,864,430 | -28% | 13.15% |
| 2. | Private Capital Management Gregg J. Powers | 1,562,000 | $55,076,120 | -16% | 5.48% |
| 3. | Luxor Capital Group Christian Leone | 1,119,400 | $39,470,044 | +22% | 2.75% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 644,918 | $22,739,809 | +222% | 0.02% |
| 5. | Ikarian Capital Neil Shahrestani | 543,047 | $19,147,837 | +197% | 1.55% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.20 | 10,000 | $302,000.00 | 2,996,130 | 2026-05-14 | Filing | |
| $29.90 | 3,500 | $104,650.00 | 814,679 | 2026-05-14 | Filing | |
| $9.97 | 20,000 | $199,400.00 | 3,815,000 | 2024-04-25 | Filing | |
| $10.15 | 8,285 | $84,092.75 | 3,795,000 | 2024-04-24 | Filing | |
| $10.29 | 11,715 | $120,547.35 | 3,786,715 | 2024-04-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.67 | 4,263 | $169,122.16 | 59,428 | 2026-03-04 | Filing | |
| $39.67 | 134,000 | $5,316,061.40 | 3,622,000 | 2026-03-04 | Filing | |
| $39.15 | 1,309 | $51,250.49 | 63,691 | 2026-03-03 | Filing | |
| $39.15 | 59,000 | $2,309,991.60 | 3,756,000 | 2026-03-03 | Filing | |
| $54.18 | 5,000 | $270,900.00 | 65,000 | 2026-02-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,552,759 | $90,010,282 | 0% | |
| 2. | 1,403,056 | $49,471,755 | 0% | |
| 3. | 579,520 | $20,428,332 | 0% | |
| 4. | 407,896 | $14,410,983 | 1.12% | |
| 5. | 296,865 | $10,467,461 | 0% |
News See All
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript
Operator: Welcome to the Harrow Health, Inc. fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Health, Inc. (NASDAQ:HROW) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Harrow Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on HROW.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Penny Insight’s Substack. In this article, we will summarize the bulls’ thesis on HROW.
Hedge Fund Resource Center